Clarity Pharmaceuticals (ASX:CU6) Accounts Payable: A$20.21 Mil (As of Dec. 2025)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.21
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Accounts Payable?

Clarity Pharmaceuticals ASX:CU6 +2.79% 39 Accounts Payable is A$20.21 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review.

Clarity Pharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2025 was A$20.21 Mil.

Clarity Pharmaceuticals's quarterly Accounts Payable declined from Dec. 2024 (A$7.79 Mil) to Jun. 2025 (A$3.21 Mil) but then increased from Jun. 2025 (A$3.21 Mil) to Dec. 2025 (A$20.21 Mil).

Clarity Pharmaceuticals's annual Accounts Payable declined from Jun. 2023 (A$2.85 Mil) to Jun. 2024 (A$2.08 Mil) but then increased from Jun. 2024 (A$2.08 Mil) to Jun. 2025 (A$3.21 Mil).

Clarity Pharmaceuticals Accounts Payable Related Terms

Clarity Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Accounts Payable Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Accounts Payable
2.85 2.85 2.08 3.21

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.98 2.08 7.79 3.21 20.21
ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$20.21 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Accounts Payable of A$20.21 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Accounts Payable too high?
Clarity Pharmaceuticals' current Accounts Payable is A$20.21 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Accounts Payable compare to VRTX and REGN?
Clarity Pharmaceuticals' Accounts Payable of A$20.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Accounts Payable is A$20.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Accounts Payable of A$20.21 Mil. The current Accounts Payable is A$20.21 Mil. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Accounts Payable is A$20.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.21
Price